Pharma BD Deal Intelligence
Novartis licensed Legend Biotech's DLL3-targeting CAR-T therapy LB2102 for small cell lung cancer in a deal worth $1,110M, giving Novartis exclusive worldwide development and commercialization rights—a modest bolt-on bet on next-generation CAR-T rather than a transformative franchise play.
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment with LB2102.
First-in-human Phase 1 (NCT05680922) of LB2102, the DLL3-targeted autologous CAR-T licensed to Novartis, in r/r SCLC/LCNEC: ORR 20% (4/20) and DCR 70% overall;…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis licensed Legend Biotech's DLL3-targeting CAR-T cell therapies including LB2102, with Novartis gaining exclusive worldwide development and commercialization rights.
34K US cases/yr · $2.8B US SCLC Therapeutics Market · <10% 5-Year Survival Rate (ES-SCLC)
Small cell lung cancer is an aggressive neuroendocrine tumor with very poor prognosis, particularly in extensive-stage disease where 5-year survival is under 10%. Novartis licensed Legend Biotech DLL3-targeting CAR-T therapy LB2102 for $100M upfront plus up to $1.01B in milestones. DLL3 is highly expressed on SCLC and other neuroendocrine tumors.
DLL3 (delta-like ligand 3) is a Notch pathway ligand highly restricted to neuroendocrine tumors including SCLC, large cell neuroendocrine carcinoma, and some prostate cancers. LB2102 combines Legend CAR-T expertise with Novartis T-Charge manufacturing platform to improve T cell fitness. Prior DLL3-targeting approaches (Rova-T ADC) failed, but CAR-T represents a differentiated modality.
Novartis paid $100M upfront for exclusive worldwide rights to LB2102 DLL3-targeting CAR-T.
Legend Biotech reported first-in-human Phase 1 results (NCT05680922) for LB2102, the DLL3-targeted autologous CAR-T licensed to Novartis, in relapsed/refractory SCLC and LCNEC: ORR 20% (4/20) and DCR 70% overall; ORR 28.6% and DCR 78.6% at higher dose levels; median duration of response 6.5 months; no dose-limiting toxicities or treatment-related deaths (CRS 30% all Grade <=2; ICANS 15%). Validates post-deal clinical progression of the licensed asset; the Novartis license remains active and ongoing.
Legend conducting Phase 1 for LB2102. First application of T-Charge platform to solid tumors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Legend Biotech Corporation (this deal) | 2023 | $1.1B | 69 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2023 deals · Novartis AG deals · Gene Therapy deals